PL1651774T3 - Zastosowanie palimorfizmów ludzkiego OATP-C związanych z wpływem na farmakokinetykę statyn u ludzi leczonych statynami - Google Patents

Zastosowanie palimorfizmów ludzkiego OATP-C związanych z wpływem na farmakokinetykę statyn u ludzi leczonych statynami

Info

Publication number
PL1651774T3
PL1651774T3 PL04743565T PL04743565T PL1651774T3 PL 1651774 T3 PL1651774 T3 PL 1651774T3 PL 04743565 T PL04743565 T PL 04743565T PL 04743565 T PL04743565 T PL 04743565T PL 1651774 T3 PL1651774 T3 PL 1651774T3
Authority
PL
Poland
Prior art keywords
statin
polymorphisms
pharmacokinetics
humans
effect
Prior art date
Application number
PL04743565T
Other languages
English (en)
Inventor
Helen Jean Ambrose
Ruth March
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PL1651774T3 publication Critical patent/PL1651774T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Semiconductor Lasers (AREA)
PL04743565T 2003-07-26 2004-07-26 Zastosowanie palimorfizmów ludzkiego OATP-C związanych z wpływem na farmakokinetykę statyn u ludzi leczonych statynami PL1651774T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0317592.4A GB0317592D0 (en) 2003-07-26 2003-07-26 Method
PCT/GB2004/003236 WO2005012566A2 (en) 2003-07-26 2004-07-26 Use of polymorphisis in human oatp-c associated with an effect on statin pharmacokinetics in humans in statin therapy
EP04743565A EP1651774B1 (en) 2003-07-26 2004-07-26 Use of polymorphisms in human oatp-c associated with an effect on statin pharmacokinetics in humans in statin therapy

Publications (1)

Publication Number Publication Date
PL1651774T3 true PL1651774T3 (pl) 2007-12-31

Family

ID=27772801

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04743565T PL1651774T3 (pl) 2003-07-26 2004-07-26 Zastosowanie palimorfizmów ludzkiego OATP-C związanych z wpływem na farmakokinetykę statyn u ludzi leczonych statynami

Country Status (12)

Country Link
US (1) US7700277B2 (pl)
EP (1) EP1651774B1 (pl)
JP (1) JP4166257B2 (pl)
AT (1) ATE373730T1 (pl)
CY (1) CY1107801T1 (pl)
DE (1) DE602004009083T2 (pl)
DK (1) DK1651774T3 (pl)
ES (1) ES2291899T3 (pl)
GB (1) GB0317592D0 (pl)
PL (1) PL1651774T3 (pl)
PT (1) PT1651774E (pl)
WO (1) WO2005012566A2 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1784504A2 (en) * 2004-07-21 2007-05-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) Oatp-c gene c463a polymorphism underlies variable response of statin therapy
WO2009106838A1 (en) * 2008-02-29 2009-09-03 Isis Innovation Limited Diagnostic methods
US9817001B2 (en) 2008-05-27 2017-11-14 Boston Heart Diagnostics Corporation Methods for determining LDL cholesterol treatment
US8470541B1 (en) 2008-09-27 2013-06-25 Boston Heart Diagnostics Corporation Methods for separation and immuno-detection of biomolecules, and apparatus related thereto
AU2012322018B2 (en) * 2011-10-13 2017-09-21 Boston Heart Diagnostics Compositions and methods for treating and preventing coronary heart disease
US9828624B2 (en) 2013-07-24 2017-11-28 Boston Heart Diagnostics Corporation Driving patient compliance with therapy
EP3220810A4 (en) 2014-11-17 2018-05-16 Boston Heart Diagnostic Corporation Cardiovascular disease risk assessment
US10572811B2 (en) * 2015-01-29 2020-02-25 Splunk Inc. Methods and systems for determining probabilities of occurrence for events and determining anomalous events
CN120795059A (zh) 2018-08-27 2025-10-17 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
CN110904215A (zh) * 2019-12-16 2020-03-24 西安和合医学检验所有限公司 用于同步检测slco1b1基因的两个snp位点的基因多态性的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US32011A (en) * 1861-04-09 Coffee-pot
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4486530A (en) * 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) * 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4543439A (en) * 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4902614A (en) * 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
GB8902689D0 (en) 1989-02-07 1989-03-30 Ici Plc Assay method
US5210015A (en) * 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
EP2423322A1 (en) 1993-11-12 2012-02-29 PHRI Properties, Inc. Hybridization probes for nucleic acid detection, universal stems, methods and kits
EP1141282A2 (en) 1998-08-07 2001-10-10 Axys Pharmaceuticals, Inc. Human anion transporter genes atnov
US20020090622A1 (en) 2000-08-23 2002-07-11 Monisola Adeokun Chemical compounds

Also Published As

Publication number Publication date
GB0317592D0 (en) 2003-08-27
CY1107801T1 (el) 2013-06-19
JP4166257B2 (ja) 2008-10-15
DE602004009083T2 (de) 2008-06-19
US20070031838A1 (en) 2007-02-08
ES2291899T3 (es) 2008-03-01
DK1651774T3 (da) 2008-01-07
ATE373730T1 (de) 2007-10-15
EP1651774B1 (en) 2007-09-19
WO2005012566A2 (en) 2005-02-10
JP2007500005A (ja) 2007-01-11
EP1651774A2 (en) 2006-05-03
WO2005012566A3 (en) 2005-06-16
PT1651774E (pt) 2007-11-16
US7700277B2 (en) 2010-04-20
DE602004009083D1 (de) 2007-10-31

Similar Documents

Publication Publication Date Title
CY1107801T1 (el) Χρηση πολυμορφισμων στον ανθρωπινο oatp-c που σχετιζονται με μια επιδραση στη φαρμακοκινητικη στατινης σε ανθρωπους σε θεραπεια στατινης
DE60310576D1 (en) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
MXPA05010819A (es) Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
WO2004103960A3 (en) Compounds and uses thereof
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2004034990A3 (en) Methods and compositions for use in treating cancer
ATE428411T1 (de) Hdl-verstärkende kombinationstherapie-komplexe
ATE353217T1 (de) 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
ATE506953T1 (de) 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel
NL1027833A1 (nl) Verbindingen bruikbaar bij therapie.
AU2003237367A8 (en) Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
DE602004020070D1 (de) Thienopyrimidin-derivate als kaliumkanal-inhibitoren
NO20040516L (no) Kombinasjonsterapi for behandling av kreft.
WO2005016883A3 (en) Acrylamide derivatives as vla-1 integrin antagonists and uses thereof
IL180138A0 (en) 2,4,6-trisubstituted pyrimidines as phosphotidylinol (pi) 3-kinase inhibitors and their use in the treatment of cancer
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
WO2005013911A3 (en) Protective and therapeutic uses for tocotrienols
TW200722098A (en) Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in pharmaceutical compositions for treating cancer
SE0301654D0 (sv) Novel compounds
NO20053903D0 (no) Nukleotidlipidesterderivater.
TR201900241T4 (tr) Vasoprotektif maddelerin kombinasyonları ve bunları içeren formülasyonlar.
UA85187C2 (en) 2-aminobenzoyl derivatives
WO2005011611A3 (en) Bicyclic compounds and compositions as pdf inhibitors
BR0308976A (pt) Terapia combinada contra tumores compreendendo derivados de acriloil distamicina substituìda e radioterapia
IL181713A0 (en) Use of il-17f for the treatment and/or prevention of neurological diseases